Sentences with phrase «first immune checkpoint»

Low - dose chemotherapy, radiation, or targeted therapies given in combination with immune checkpoint blockade may prove to be an effective and efficient way to immunize the body against tumor cells,» says CRI Scientific Advisory Council associate director James P. Allison, Ph.D., who identified the first immune checkpoint blockade with his discovery in 1995 that the cytotoxic T lymphocyte antigen - 4 (CTLA - 4) receptor inhibited T cell responses.

Ipilimumab targets the CTLA - 4 checkpoint on T cells and was the first immune checkpoint inhibitor.

Not exact matches

BMS's drug, ipilimumab (Yervoy), was the first checkpoint inhibitor (a kind of cancer immunotherapy drug that essentially helps the immune system release its brake and go after tumor cells it might normally miss) to get approved in the US in 2011 for melanoma.

In my experience, this marks both the first clinical trial of an approved drug with an effect on survival in advanced melanoma in the adjuvant setting, and, in this same setting, the first to study an immune checkpoint inhibitor in the adjuvant setting.

«This is one of the first clinical trials testing an immune checkpoint inhibitor in glioblastoma,» says Rixe.

ALEXANDRIA, VA, FORT WASHINGTON, PA. — Immunotherapy with immune checkpoint inhibitors is the first of a new generation of immunotherapy treatments, revolutionizing treatment for many different types of cancer.

The first generation of immunotherapies, including immune checkpoint inhibitors and cancer vaccines, have been limited by the proportion of patients who benefit, and by the depth and duration of response in those that do.

The first three drugs are checkpoint inhibitors that «take the brakes off» the immune system and enable it to fight cancer; the last is an oncolytic virus therapy that stimulates stronger anti-tumor immune responses.

Led by Leena Gandhi, MD, PhD, associate professor of medicine and director of thoracic medical oncology, researchers from the KEYNOTE - 021 study demonstrated for the first time that combining an immune checkpoint inhibitor — in this case, pembrolizumab — with a platinum - doublet chemotherapy regimen might be more effective than chemotherapy alone as first - line treatment for advanced, non-squamous NSCLC.

Following the 2011 FDA approval of ipilimumab (Yervoy ®), an immune checkpoint inhibitor drug, the first milestone toward this goal was achieved.

It is also the first in an emerging class of therapies called «checkpoint blockade,» which enhance the immune system's ability to attack cancer by interfering with immunological checkpoints that slow or stop immune cell activation and proliferation in the presence of tumors or chronic viral infection.